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Abstract
Objective: The objective of this selective EBM review is to determine whether or not Platelet
Rich Plasma is efficacious in regrowth of hair in both androgenic alopecia and alopecia areata.
Study Design: Review of two blinded randomized controlled trials and one prospective cohort
study. Populations studied were Adults over 18 with hair loss. All articles published in peerreviewed journals in English.
Data Source: 3 articles found via PubMed and NCBI
Outcomes Measured: One prospective cohort study, and two randomized control trials evaluating
hair regrowth after PRP scalp injections. Outcomes were reported by patient satisfaction, mean
hair increase and hair regrowth in hair loss areas.
Results: Gentile (2015) enrolled 23 patients with androgenic alopecia, with 3 withdrawals. After
PRP injection a mean increase in total hair density of 45.9 hairs per cm2 compared with baseline
was observed at 3 months. Ginki (2014) enrolled 22 volunteers with androgenic alopecia, with 2
withdrawals. Hair densities were reported at monthly intervals with the highest reported at 4
months: 170.70 plus or minus 37.81 hairs. Trink (2013) enrolled 45 patients with alopecia areata,
with no withdrawals. 60 percent of the patients in the PRP group had complete remission of
alopecia as compared to placebo.
Conclusion: PRP injection for androgenetic alopecia and alopecia areata is a simple, safe and
cost effective treatment for hair loss or thinning.
Key words: Hair loss, PRP injection, platelet rich plasma, PRP and hair growth.
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Introduction
Androgenic alopecia (AGA) and alopecia areata (AA) are common hair loss disorders
affecting adult populations worldwide. Alopecia areata is an autoimmune cause of hair loss and
most common type in younger populations. Androgenic alopecia, also known as male pattern
hair loss (MPHL) is the most common form of alopecia and affects up to 80% of white men and
40% of women. 1 With such a strong prevalence, Physician Assistants in any field, certainly
dermatology, can expect to council patents on alopecia throughout their careers.
The etiology of male pattern hair loss is androgen-dependent, and a genetically
determined trait. Dihydroxytestosterone (DHT) synthesized from testosterone by an enzyme
called 5apha-reductase is thought to be the principal agent for MPHL.4 DHT binds preferentially
to hair follicles, as compared to testosterone. Males with AGA have consistent higher levels of
DHT and 5alpha-reducatase as compared to non-balding counterparts.4
Female pattern hair loss (FPHL) (or female androgenetic alopecia) is believed to be the
same entity.4 However, the requirement of androgens is less clear-cut than in men and the
distribution of hair loss is generally different.4 In both men and women normal hair follicles
follow a life cycle where the hair follicle undergoes a phase of rapid growth (anagen) to a resting
period (telogen). In both men and women, AGA is characterized by an ongoing decline in the
duration of anagen, and increase in the duration of telogen and miniaturization of scalp hair
follicles.4
Alopecia areata (AA) is a common autoimmune condition, causing inflammation induced
hair loss. According to the National Alopecia Areata Foundation Over 6.6 million people in the
United States and 147 million worldwide have or will develop alopecia areata at some point in
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their lives. It is a common cause of abrupt-onset hair loss, with both sexes affected equally.
Clinically presents with well-demarcated round or oval bald spots on the scalp or other parts of
the body.4 Although it may occur at any age, alopecia areata is the most common form of
alopecia seen in children. Currently no FDA approved treatment exists.3
There is no exact number for health care visits or cost on health care system related to
treating alopecia. With such a variability in treatment options and the cosmetic nature of the
disease, figures reported are not consistent. Currently two FDA approved pharmaceuticals exist
for androgenic alopecia: Topical Minoxidil and oral finasteride. Oral finasteride is a 5alphareductase inhibiter which prevents conversion of testosterone to DHT. The side effect profile
includes decreases sex drive or ability.6 Minoxidil, a piperidinopyrimidine derivative, was noted
to cause hypertrichosis when administered orally as an antihypertensive.4 It is now used as a 2%
and a 5% topical treatment in a lotion or foam preparation.4 The mechanism of action is not fully
understood. Clinical trials in only the vertex region of the scalp have shown regrowth in up
30%–45% of patients. 4 Some patients experience an increased shedding in the first 4–6 weeks of
application.4 Once started Minoxidil has to be taken indefinitely, with discontinuation any
potential hair regrowth will return to baseline.
Hair Restoration Surgery stands as the most definitive treatment. The most advanced
method is Follicular Unit Transplant (FUE). With this procedure, hair follicles are extracted from
the occipital and parietal region. Hair from this region is generally resistant to androgenic
alopecia and placed in desired areas, usually from the frontal to crown regions. Hair transplant
prices vary by region and clinic, but the range is typically from $2 to $10 per graft, with $4-5 per
graft being the average.5 The total cost can range anywhere from $2,500 to $20,000.5 Transplant
is classically permanent, however pattern hair loss of non- transplanted hair will continue. With
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the invasive nature of the procedure and high cost there continues to be room for advancement in
treatment of androgenic alopecia and alopecia areata.
Platelet Rich Plasma (PRP) has emerged as a new treatment modality in regenerative
plastic surgery and preliminary evidence suggests it might have a beneficial role in hair
regrowth.. Platelet Rich Plasma is defined as an autologous concentration of plasma with a
greater count of platelets than that of whole blood.2 Using the patient’s own blood, PRP is
extracted. It’s action depends on the released growth factors from platelets. It has been
investigated and used in numerous fields of medicine. Proponents of PRP technology suggest
that its benefits include hard and soft tissue wound healing, and it is used in this manner in
orthopedics, dermatology, maxillofacial surgery and plastic surgery.1, 2 PRP injection pricing
varies by region with average price around 600-800 US Dollars per treatment.4
Currently PRP is being investigated for hair regrowth with limited published data
available. No published trials exists for using PRP in treatment alopecia areata. As a mechanism
for hair growth Activated PRP seems to promote numerous growth factors. These include
activation of transforming growth factor, platelet derived growth factor, vascular endothelial
growth factor, epidermal growth factor and insulin like growth factor.1 It is proposed that these
factors released from platelets act on the stem cells at the base of the follicle to promote growth
and revascularization.2 This paper will evaluate these preliminary findings in both alopecia
areata and androgenic alopecia.
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Objective
The objective of the selective EBM review is to determine whether or not Platelet Rich
Plasma Injection is Efficacious in Treatment of Hair Loss in Androgenic Alopecia and Alopecia
Areata?
Methods
In selecting the studies for this review, the author applied the following criteria. The
enrolled populations had to be at least 18 years old with hair loss of non-traumatic etiology of
either androgenic alopecia or alopecia areata. Inclusion: Adults over 18 year old with hair loss,
Patient suitable for PRP injection from a surgical point of view. This entailed scalp free of any
skin condition such as keloids, cellulitis, any break in skin integrity or hematologic pathology
rendering scalp injection high risk. The alopecia areata group had to have recurrent disease of at
least 2 years duration. Exclusion criteria: Any medical or drug related hair loss. Platelet disorder,
thrombocytopenia, bone marrow aplasia, uncompensated diabetes, sepsis, cancer,
antiaggregating therapy, systemic or topical treatment for male pattern hair loss in past 6 months
for Gkini, and 12 months for Gentile. Topical drugs in exclusion criteria included Minoxidil,
prostaglandin, analogs, retinoids, and corticosteroids. (Please see Table 1 for details of inclusion/
exclusion criteria and patient demographics)
Table 1: Demographics and Characteristics of included studies
Study

Gentile1
(2015)

Type

#Pt Age
s
(yrs)

Inclusion Criteria

Exclusion Criteria

W/
D

RCT

23

Age 19-63, male
pattern hair loss
Stage IIa-Stage IV
according to the
Norwood-

Platelet disorder,
thrombocytopenia
antiaggregating therapy,
systemic treatment for
male pattern hair loss in

3

1963

Inter
venti
ons
PRP
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Hamilton
classification,
suitable for PRP
injection.
Gkini2
(2014)

Prospe
ctive
Cohort
Study

22

2472

Trink3
(2013)

RCT

45

>18

past 12 months, bone
marrow aplasia,
uncompensated diabetes,
sepsis, cancer, immune
compromised and
keloids.
Volunteers over 18 Present history of
years of age with
immunosuppression
diagnosed
(malignancy,
androgenic
chemotherapy, steroid
alopecia, Had not
therapy), dermatological
received any
disease affecting the
topical or systemic scalp, autoimmune
treatment for their disorders, hematologic
hair loss during the disorders, platelet
last 6 months.
dysfunction syndrome
and on anticoagulation
therapy, Aspirin or
NSAIDs discontinued
use 7 days before
treatment/ Any other
cause of hair loss.
45 male and
Any medical conditions
female otherwise
or other scalp or hair
healthy patients
disease
with chronic,
recurring alopecia
areata, of at least 2
years duration.
Having between
four and 6
symmetrically
distributed patches
of hair loss.

2

PRP

0

PRP

Search Strategy
All studies had to be published in peer reviewed journals in English, no earlier than 2013.
The author searched the articles via PubMed, NCBI, and Medline. Key words: hair loss, PRP
injection, PRP and hair growth, platelet rich plasma. Articles were selected based on relevancy
and if they included patients oriented outcomes, i.e. (hair regrowth).
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Outcomes Measured
The intervention had to be PRP scalp injection using patients own blood with the
outcomes measured being hair regrowth and mean hair increase. The three articles evaluated
include one prospective cohort study, and two randomized control trials evaluating hair regrowth
after PRP scalp injections. The prospective study by Trink had no comparison groups, all
patients were injected treated with PRP and followed for hair regrowth. The RCT by Gentile and
Gkini included a placebo and treatment group. Statistics reported or used: RRR, ARR, NNT, and
P-values. How are they measured: Dermoscopic evaluation of scalp for Hair regrowth in bald
spots, Patient satisfaction, Mean +/- standard deviation of hairs, mean hair increase.
Results
In all studies PRP was obtained by peripheral venous access, withdrawing and
centrifuging patients’ blood. Interfollicular injection of PRP was performed by experienced
Physicians in each of the studies. In the study by Gentile, 23 patients were enrolled with 3 that
withdrew and were not included in statistical analysis. Outcomes were measured by mean hair
increase after PRP injection. All patients were evaluated at beginning of study, 2months, 6, 12,
16 and 24 months. The results of this study showed a significant increase in the mean hair count
for the treatment area after 3 months (3 months vs. 0 month), with a mean increase of 33.6 hairs
in the target area compared with baseline, while the control area showed a mean decrease of 3.2
hairs (control vs. treatment: p , .0001). Accordingly, in the treatment area, a mean increase in
total hair density of 45.9 hairs per cm2 compared with baseline was observed after 3 months, and
the control area displayed a mean decrease of 3.8 hairs per cm2) in hair density at the same time
(control vs. treatment: p,.0001). In addition, terminal hair density improved significantly by 40.1
hairs per cm2 in the treatment area compared with baseline, while it decreased by 5.6 hairs per
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cm2 in the control area of the scalp (control vs. treatment: p = .0003). There were no statistically
significant differences in villus hair density between the study and the control area after 3
months.
In the Study by Ginki, 22 volunteers (20 men, 2 women) with androgenic alopecia were
enrolled. Of the 22 patients enrolled, 2 withdrew and were not included in statistical analysis.
The outcomes were measured by satisfaction questioner and mean hair increase. Hair regrowth
satisfaction surveys reported a high satisfaction rate of 7.1 on a 1-10 scale. 85% of Patients of
patients reported an improvement in hair quality and thickness. 65% of patients reported an
increase in hair density.
Additionally mean Hair densities were reported at many time intervals of treatment. All
tests were two tailed with P values less than .05. Time intervals were in months. Hair density
(hair/cm2) significantly increased at T3 (154.80 ± 34.39), at T4 (170.70 ± 37.81) at T5 (156.23 ±
37.75) and at T6 (153.70 ± 39.92) (P < 0.001) compared to the onset of therapy (T1). The highest
hair density recorded was at T4 (4 months post PRP injection).2 The percent increase rate from
baseline (T1) was 0.45%, 8.18%, 19.9%, 9.19% and 7.41% at T2, T3, T4, T5 and at T6,
respectively.2 Regarding failure rate none of the patients presented decreased hair density
compared to that of baseline. One patient reported no change in hair density or growth at T3 and
T4. At T5 (5 months past treatment) one patient a decrease of 1 hair/cm2 in hair density
comparing to that of T1. And at T6 30% of patients presented a mean decrease of 2 hair/cm2.
Trink enrolled 45 patients with alopecia areata (20 men, 25 women, mean age 28 years).
No patients were excluded from the study. Patient were randomized and 15 patients received
placebo, 15 received PRP injection and 15 received a TrA (triamcinolone acetonide) which is a
treatment option for alopecia areata not approved by the FDA. Outcomes were measured by
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dermoscopic evaluation of scalp for Hair regrowth in alopecia areata bald spots. PRP Platelet
Rich Plasma was found to increase hair growth significantly and to decrease hair dystrophy as
compared to placebo. 60 percent of the patients in the PRP group had complete remission of
alopecia as compared to placebo. A numbers needed to treat (NNT) analysis shows that a PA
would need to treat 3 patients with platelet rich plasma to prevent 1 patient from having
continued bald spots, compared with control.
Safety: Patients own blood was used for all three PRP injection studies. No adverse reactions or
events were reported. Lidocaine was used to anesthetize the scalp so the procedure was very
tolerable.
Discussion
Androgenic Alopecia remains the most common hair disorder without satisfactory
treatment. Due to the shortened anagen phase and diminishing hair follicle, characteristic of AA,
current therapeutic therapies target proliferation during the hair cycle. Numerous products have
been proposed with only minoxidil and finasteride approved by the FDA. Minoxidil prolongs
anagen phase and increases hair follicle size.2 Finasteride has been shown to reduce pattern hair
loss associated with increased expression of caspases and apoptosis related androgen.2 However,
these medications have their limitations in efficacy, compliance, and patient satisfaction.
Additionally a variety of both topical and systemic side effects exist, with erectile dysfunction as
an example. Hair transplant is currently the most definitive option but comes with a high cost,
downtime from work and dependence on donor area for hair grafts. The search continues for new
treatment option for alopecia.
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Presently PRP is being investigated for hair regrowth with limited published data
available. Alopecia areata is an autoimmune cause of hair loss, without any FDA approved
treatment modality. Furthermore, no published trials exist for using PRP in treatment of alopecia
areata. As a mechanism for hair growth Activated PRP seems to promote numerous growth
factors. PRP induced activation of antiapoptotic regulators such as Bcl-2 protein and Aktsignaling, which prolongs survival of dermal papilla cells during the hair cycle.2 This activation
also includes transforming growth factor, platelet derived growth factor, vascular endothelial
growth factor, epidermal growth factor and insulin like growth factor.1 It is proposed that these
factors released from platelets act on the stem cells at the base of the follicle to promote growth
and revascularization, prolonging the anagen phase of the hair cycle.2
In summary, Gentile (2015) enrolled 23 patients with androgenic alopecia, with 3
withdrawals. After PRP injection a mean increase in total hair density of 45.9 hairs per cm2
compared with baseline was observed at 3 months. Ginki (2014) enrolled 22 volunteers with
androgenic alopecia, with 2 withdrawals. Hair densities were reported at monthly intervals with
the highest reported at 4 months: 170.70 plus or minus 37.81 hairs. Trink (2013) enrolled 45
patients with alopecia areata, with no withdrawals. 60 percent of the patients in the PRP group
had complete remission of alopecia as compared to placebo. With these combined results it is
clear that Platelet Rich plasma is efficacious treatment for both androgenic alopecia and alopecia
areata.
Some sources error might include lack of common reference protocol for PPR
preparation and injection. For example, volumes of PRP injected varied between studies or was
not specified. Different brands of equipment were used with different physicians injecting the
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scalp. Time intervals of injection and frequency also varied. The degree of hair loss also varied
between patients, although this would be a nearly impossible variable to control.
Conclusion
PRP injection for androgenetic alopecia and alopecia areata is a simple, safe and cost
effective treatment for hair loss or thinning. The product is entirely from the patient’s own blood
so any adverse effects are unlikely. The results showed reasonable improvement in hair loss,
however far from complete resolution of alopecia. With only a handful of peer reviewed articles
on PRP injection, clinical evidence is still weak. Future studies should incorporate a much larger
sample size. I think it would also be beneficial for a board of PRP super-users to define an
unequivocal reference protocol. This should including explicit placement instruction for PRP
injection with set volume and details on increments into the scalp.
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